Molecular diagnostics start-up InSilixa, Inc. specializes in high-performance CMOS biochips for applications in microarray technology, qPCR, and DNA sequencing. InSilixa's technology includes novel methods for producing metal-oxide semiconductors (CMOS) chips in a cost-efficient and mass-deployable means. The firm's platform technology is a point-of-care system that can rapidly identify pathogens in clinical samples including whether - for example - such pathogens are antibiotic resistant. The technologies that underpin InSilixa's point-of-care system are exclusively licensed from Caltech, The University of Texas at Austin, and Stanford University.
